Nebivolol Accord (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebivolol Accord, is a beta blocker presented as an oral tablet for systemic use. It is prescribed to lower elevated blood pressure and improve cardiac function in adults with hypertension or heart failure.

GNH USA supplies Nebivolol Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from comprehensive regulatory support and consistent product availability across multiple markets.

Nebivolol is a beta‑blocker indicated for conditions related to elevated blood pressure and cardiac dysfunction.

- Hypertension: reduces systolic and diastolic blood pressure, helping patients achieve target levels. - Heart failure: improves left ventricular ejection fraction and alleviates symptoms in mild to moderate chronic heart failure. - Left ventricular dysfunction: enhances cardiac output and may delay progression of ventricular remodeling in patients with impaired ventricular function.

Nebivolol may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate headache reported during early therapy. - Dizziness: transient dizziness, especially when standing quickly. - Fatigue: general tiredness or lack of energy. - Nasal congestion: feeling of a blocked nose. - Diarrhea: loose stools occurring occasionally. - Cough: dry cough without infection.

Serious or Rare Side Effects: - Bradycardia: abnormally slow heart rate that may require medical attention. - Severe hypotension: marked drop in blood pressure leading to fainting. - AV block: atrioventricular conduction disturbances. - Bronchospasm: airway constriction, particularly in patients with asthma. - Anaphylaxis: rare severe allergic reaction. - Liver enzyme elevation: significant increase in hepatic transaminases.

Before initiating Nebivolol therapy, clinicians should consider several safety precautions to minimize risks. - Blood pressure monitoring: regularly assess blood pressure to ensure therapeutic response and avoid hypotension. - Cardiac assessment: evaluate heart rate and conduction system, especially in patients with bradycardia or AV block history. - Respiratory caution: use with care in patients with asthma or chronic obstructive pulmonary disease due to potential bronchoconstriction. - Discontinuation: avoid abrupt cessation; taper dose gradually to prevent rebound hypertension. - Renal impairment: adjust dosing and monitor renal function in patients with moderate to severe kidney disease. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Nebivolol can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Combined beta‑blockers: additive cardiac depression and excessive bradycardia. - Calcium‑channel blockers verapamil or diltiazem: increased risk of AV block and bradycardia. - Potent CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): elevated nebivolol plasma concentrations. - Severe bradyarrhythmias: concurrent use with drugs that further depress heart rate. - Antihypertensive polytherapy: may cause profound hypotension when combined with multiple blood‑pressure agents.

Moderate Interactions (Monitor Closely): - Diuretics: monitor electrolytes and blood pressure for additive hypotensive effect. - ACE inhibitors or ARBs: observe for enhanced blood pressure reduction. - NSAIDs: may attenuate antihypertensive effect, requiring dose adjustment. - Antiarrhythmic agents (e.g., amiodarone): watch for conduction abnormalities. - Antidiabetic drugs: monitor blood glucose as beta‑blockade can mask hypoglycemia symptoms.